{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:13:53Z","timestamp":1786986833302,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003035","name":"Aase og Ejnar Danielsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010809","name":"Jascha Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011076","name":"Simon Fougner Hartmann's Family Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008242","name":"Direkt\u00f8r Ejnar Jonasson Kaldet Johnsen og Hustrus Mindelegat","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"K\u00f8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008361","name":"Scleroseforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clim.2025.110608","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:56:03Z","timestamp":1760223363000},"page":"110608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cerebrospinal fluid exosomal Epstein-Barr virus microRNAs in multiple sclerosis and effects of disease modifying therapies"],"prefix":"10.1016","volume":"281","author":[{"given":"Victoria Hyslop","family":"Hvalkof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene Bredahl","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahla","family":"El Mahdaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Mathilde","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe Romme","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Buhelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle Bach","family":"S\u00f8ndergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clim.2025.110608_bb0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.clim.2025.110608_bb0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.clim.2025.110608_bb0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","article-title":"Clinically isolated syndromes","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.clim.2025.110608_bb0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1474-4422(23)00377-0","article-title":"Blood-brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies","volume":"23","author":"Zierfuss","year":"2024","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.clim.2025.110608_bb0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-020-00704-w","article-title":"Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis","volume":"34","author":"Sellebjerg","year":"2020","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.clim.2025.110608_bb0030","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/acn3.52009","article-title":"CD11c(+) B cells in relapsing-remitting multiple sclerosis and effects of anti-CD20 therapy","volume":"11","author":"El Mahdaoui","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.clim.2025.110608_bb0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","article-title":"Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients","volume":"180","author":"Cross","year":"2006","journal-title":"J. Neuroimmunol."},{"issue":"26","key":"10.1016\/j.clim.2025.110608_bb0040","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1016\/j.cell.2023.11.015","article-title":"Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis","volume":"186","author":"Vietzen","year":"2023","journal-title":"Cell"},{"issue":"6460","key":"10.1016\/j.clim.2025.110608_bb0045","article-title":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility","volume":"365","year":"2019","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.clim.2025.110608_bb0050","first-page":"160","article-title":"Epstein\u2013Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"19","author":"Bjornevik","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"11","key":"10.1016\/j.clim.2025.110608_bb0055","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41584-024-01167-9","article-title":"Epstein\u2013Barr virus as a potentiator of autoimmune diseases","volume":"20","author":"Robinson","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.clim.2025.110608_bb0060","first-page":"160","article-title":"Epstein\u2013Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"19","author":"Bjornevik","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"6578","key":"10.1016\/j.clim.2025.110608_bb0065","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"1979","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.clim.2025.110608_bb0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan MicroRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"issue":"7893","key":"10.1016\/j.clim.2025.110608_bb0075","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41586-021-04234-3","article-title":"MicroRNA sequence codes for small extracellular vesicle release and cellular retention","volume":"601","author":"Garcia-Martin","year":"2022","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.clim.2025.110608_bb0080","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/1352458519879303","article-title":"microRNA and exosome profiling in multiple sclerosis","volume":"26","author":"Mycko","year":"2020","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.clim.2025.110608_bb0085","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12250-017-3996-5","article-title":"An update: Epstein-Barr virus and immune evasion via microRNA regulation","volume":"32","author":"Zuo","year":"2017","journal-title":"Virol. Sin."},{"key":"10.1016\/j.clim.2025.110608_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1297994","article-title":"Epstein-Barr virus: the mastermind of immune chaos","volume":"15","author":"de Silva","year":"2024","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.clim.2025.110608_bb0095","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1177\/1352458513488232","article-title":"Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis","volume":"19","author":"Teunissen","year":"2013","journal-title":"Mult. Scler."},{"issue":"14","key":"10.1016\/j.clim.2025.110608_bb0100","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1177\/1352458517690618","article-title":"Age related multiple sclerosis severity score: disability ranked by age","volume":"23","author":"Manouchehrinia","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clim.2025.110608_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.744509","article-title":"Plasma exosome-enriched extracellular vesicles from lactating mothers with type 1 diabetes contain aberrant levels of miRNAs during the postpartum period","volume":"12","author":"Fr\u00f8rup","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.clim.2025.110608_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136133","article-title":"Characterization of RNA from exosomes and other extracellular vesicles isolated by a novel spin column-based method","volume":"10","author":"Enderle","year":"2015","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.clim.2025.110608_bb0115","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","article-title":"Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls","volume":"17","author":"Yilmaz","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"2","key":"10.1016\/j.clim.2025.110608_bb0120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1057\/jt.2009.5","article-title":"The correlation coefficient: its values range between +1\/\u22121, or do they?","volume":"17","author":"Ratner","year":"2009","journal-title":"J. Target. Meas. Anal. Mark."},{"issue":"11","key":"10.1016\/j.clim.2025.110608_bb0125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41584-024-01167-9","article-title":"Epstein\u2013Barr virus as a potentiator of autoimmune diseases","volume":"20","author":"Robinson","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.clim.2025.110608_bb0130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.molmed.2019.11.003","article-title":"Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.clim.2025.110608_bb0135","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000872","article-title":"EBNA-1 titer gradient in families with multiple sclerosis indicates a genetic contribution","volume":"7","author":"Mescheriakova","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"issue":"3","key":"10.1016\/j.clim.2025.110608_bb0140","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.msard.2013.12.004","article-title":"Multiple sclerosis therapy and Epstein-Barr virus antibody titres","volume":"3","author":"Raffel","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.clim.2025.110608_bb0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12951-018-0437-z","article-title":"Exosome origin determines cell targeting and the transfer of therapeutic nanoparticles towards target cells","volume":"17","author":"Sancho-Albero","year":"2019","journal-title":"J. Nanobiotechnol."},{"issue":"4","key":"10.1016\/j.clim.2025.110608_bb0150","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000466","article-title":"Molecular signature of Epstein-Barr virus infection in MS brain lesions","volume":"5","author":"Moreno","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"14","key":"10.1016\/j.clim.2025.110608_bb0155","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0b013e3181d865a1","article-title":"Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis","volume":"74","author":"Sargsyan","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.clim.2025.110608_bb0160","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/archneurol.2011.971","article-title":"Immunological markers of optimal response to Natalizumab in multiple sclerosis","volume":"69","author":"Villar","year":"2012","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.clim.2025.110608_bb0165","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/brain\/awaf027","article-title":"EBV-specific T-cell responses are telling us something important about multiple sclerosis","volume":"148","author":"Giovannoni","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.clim.2025.110608_bb0170","article-title":"The oncogenic role of miR-BART19-3p in Epstein-Barr virus-associated diseases","volume":"2020","author":"Zhang","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.clim.2025.110608_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1371743","article-title":"Granzymes in health and diseases: the good, the bad and the ugly","volume":"15","author":"Cigalotto","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2025.110608_bb0180","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/viro.2001.1020","article-title":"Preferential utilization of the perforin\/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4+ T cells","volume":"287","author":"Khanolkar","year":"2001","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.clim.2025.110608_bb0185","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1021\/acs.molpharmaceut.8b00985","article-title":"Cluster of differentiation 46 is the major receptor in human blood-brain barrier endothelial cells for uptake of exosomes derived from brain-metastatic melanoma cells (SK-Mel-28)","volume":"16","author":"Kuroda","year":"2019","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.clim.2025.110608_bb0190","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12987-022-00359-3","article-title":"Extracellular vesicles through the blood-brain barrier: a review","volume":"19","author":"Ramos-Zald\u00edvar","year":"2022","journal-title":"Fluids Barriers CNS"},{"issue":"9","key":"10.1016\/j.clim.2025.110608_bb0195","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1096\/fj.03-1094fje","article-title":"Adhesion and signaling by B cell-derived exosomes: the role of integrins","volume":"18","author":"Clayton","year":"2004","journal-title":"FASEB J."},{"issue":"18","key":"10.1016\/j.clim.2025.110608_bb0200","doi-asserted-by":"crossref","first-page":"10334","DOI":"10.1128\/JVI.01310-13","article-title":"Exosomes derived from Epstein-Barr virus-infected cells are internalized via caveola-dependent endocytosis and promote phenotypic modulation in target cells","volume":"87","author":"Nanbo","year":"2013","journal-title":"J. Virol."},{"issue":"1\u20132","key":"10.1016\/j.clim.2025.110608_bb0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jneuroim.2010.08.003","article-title":"Epstein-Barr virus infection of human brain microvessel endothelial cells: a novel role in multiple sclerosis","volume":"230","author":"Casiraghi","year":"2011","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.clim.2025.110608_bb0210","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000975","article-title":"Anti-CD20 disrupts meningeal B-cell aggregates in a model of secondary progressive multiple sclerosis","volume":"8","author":"Roodselaar","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.clim.2025.110608_bb0215","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/v15030714","article-title":"Epstein\u2013Barr virus history and pathogenesis","volume":"15","author":"Yu","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.clim.2025.110608_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.clim.2025.110608_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103136","article-title":"Circulating levels of tight junction proteins in multiple sclerosis: association with inflammation and disease activity before and after disease modifying therapy","volume":"54","author":"Olsson","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clim.2025.110608_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578128","article-title":"Cerebrospinal fluid soluble CD27 is associated with CD8(+) T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis","volume":"381","author":"El Mahdaoui","year":"2023","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.clim.2025.110608_bb0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ana.24408","article-title":"Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis","volume":"78","author":"Komori","year":"2015","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.clim.2025.110608_bb0240","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000872","article-title":"EBNA-1 titer gradient in families with multiple sclerosis indicates a genetic contribution","volume":"7","author":"Mescheriakova","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clim.2025.110608_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104497","article-title":"The concentrations of antibodies to Epstein-Barr virus decrease during ocrelizumab treatment","volume":"70","author":"Pham","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.clim.2025.110608_bb0250","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200217","article-title":"Disease-modifying treatments for multiple sclerosis affect measures of cellular immune responses to EBNA-1 peptides","volume":"11","author":"Dungan","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.clim.2025.110608_bb0255","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1074-7613(00)80493-8","article-title":"Is EBV persistence in vivo a model for B cell homeostasis?","volume":"5","author":"Khan","year":"1996","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.clim.2025.110608_bb0260","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1038\/emboj.2012.63","article-title":"EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency","volume":"31","author":"Riley","year":"2012","journal-title":"EMBO J."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625001834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625001834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T19:34:43Z","timestamp":1779737683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661625001834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":52,"alternative-id":["S1521661625001834"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2025.110608","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerebrospinal fluid exosomal Epstein-Barr virus microRNAs in multiple sclerosis and effects of disease modifying therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2025.110608","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110608"}}